Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases

Clinical Infectious Diseases

Volumn 26, Issue 6, 1998, Pages 1383-1396

  Walsh, Thomas J ^c   Hiemenz, John W ^d   Seibel, Nita L ^d   Perfect, John R ^d   Horwith, Gary ^d   Lee, Lily ^d   Silber, Jeffrey L ^d   DiNubile, Mark J ^d   Reboli, Annette ^d   Bow, Eric ^d   Lister, John ^a   Anaissie, Elias J ^b  

^a W Pennsylvania Cancer Institute   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC MYCOSIS;

EID: 17344368128     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516353     Document Type: Article

References (27)

1. Rex J, Walsh TJ, Anaissie E. Fungal infections in iatrogenically compromised hosts. Adv Intern Med 1998;43:321-72.
2. Graybill JR. The future of antifungal therapy. Clin Infect Dis 1996;22(suppl 2):S166-78.
3. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
4. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 1990;5:94-108.
5. Maddux MS, Barrier SL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1990;14:177-81.
6. Miller RP, Bates JH. Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 1969;71:1089-95.
7. Sarosi GA. Amphotericin B: still the "gold standard" for antifungal therapy. Postgrad Med 1990;88:151-66.
8. Fromtling RA. Amphotericin B lipid complex. Drugs Future 1995;20:129-34.
9. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Nail Acad Sci USA 1988;85:6122-6.
10. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451-71.
11. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochem Biophys Acta 1992;1107:271-82.
12. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-21.
13. Allendoerfer R, Yates RR, Sun SH, Graybill JR. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992;30:377-84.
14. Mitsutake K, Kohno S, Miyazaki, et al. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 1994;128:13-7.
15. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994;33:73-81.
16. Swenson CE, Janoff AS. Preclinical studies with amphotericin B lipid complex. Drugs Today 1996;32:397-402.
17. Krawiec DR, McKiernan BC, Twardock AR, et al. Use of amphotericin B lipid complex for treatment of blastomycosis in dogs. J Am Vet Med Assoc 1996;209:2073-5.
18. Pannuti CS, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant: attributable mortality and risk factors. Cancer 1992;69:2653-62.
19. Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: analysis of risk factors and clinical manifestations. Neurology 1985;35:1654-7.
20. Rabodonirina M, Piens MA, Monier MF, Gueho E, Fiere D, Mojon M. Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis 1994;13:152-61.
21. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997;90:999-1008.
22. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.
23. Lecciones JA, Lee JW, Navarro E, et al. Vascular catheter-associated fungemia in cancer patients: analysis of 155 episodes. Rev Infect Dis 1992;14:875-83.
24. Bow EJ, Shore TB, Kilpatrick MG, Scott BA, Schacter B. Relationship of invasive fungal disease and high-dose cytarabine plus etoposide containing remission-induction regimens for acute myeloid leukemia. Blood 1991;78(suppl):55A.
25. Mehta T, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochemica et Biophysica Acta 1984;770:230-4.
26. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991;43:831-5.
27. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994;38:223-7.